SNAP tag A3 AdenosineR cloned plasmid
Tag-lite plasmid cloned with a SNAP tag A3 Adenosine receptor
Tag-lite cells transiently expressing the A3 receptor labeled with Terbium for use in receptor binding applications. The cells are provided ready to use.
A3 receptor is one of the four adenosine receptor family (including A1, A2A, and A2B receptors). A3 receptor is implicated in various pathological conditions, such as cardiac and cerebral ischaemia, and neurodegenerative diseases, as well as inflammatory pathologies including rheumatoid arthritis and asthma. Thus, it is considered as an interesting therapeutic target.
Cells expressing the A3 receptor are provided pre-labeled with Terbium, and can be used to conduct receptor binding studies on the aforementioned receptor.
Running your A3 receptor binding assay using Tag-lite is as easy as it can get. Simply dispense 10 µL of labeled cells (C1TT1A3) into each well, followed by 5 µL of labeled ligand (L0069GRE) and 5 µL of the compound you wish to test. Like all HTRF assays, Tag-lite assays do not require any washing steps. A diagram of the procedure to be followed is given on the right.
A saturation binding assay measures total and non-specific binding for increasing concentrations of ligand under equilibrium conditions. To perform the assay, the fluorescent ligand is titrated into a solution containing a fixed amount of labeled cells, and then incubated to equilibrium. The HTRF Ratio obtained from this titration is the total binding.
A competitive binding assay is performed to measure the dissociation constant, Ki. To perform the assay, the compound is titrated into a solution containing a fixed concentration of fluorescent ligand and a fixed amount of cells.
Examples of data obtained using Adenosine A3 receptor labeled cells and their matching fluorescent ligand (L0069GRE). XAC (Xanthine amine congener) was used for Ki determination in the competitive binding assay. Results may vary from one HTRF® compatible reader to another.
Adenosine receptors designated by four subtypes A1, A2A, A2B and A3 were shown to be promising pharmacological targets for the development of therapeutic compounds for various therapeutic areas such as cancer, neurodegenerative disease and COPD/Asthma. Thus, a wide range of compounds, and particularly antagonists have been largely studied.
The Tag-Lite® binding assay platform offers the complete adenosine receptors subset A1, A2A, A2B and A3 to characterize compounds in term of binding affinity (Ki) and selectivity profile.
The set of compounds have been profiled on A1, A2A, A2B and A3 receptors using their respective fluorescent ligands L0067RED, L0058RED, L0068RED and L0069GRE.The selectivity profiles of several compounds involved in different therapeutic areas were assessed with this Tag-Lite platform.
The table below summarizes the resulting Ki obtained for each receptor subtype for the full panel of compounds. The results are confirming the expected selectivity and the range of affinities for these reference compounds.
|Compound||Pharmacological class||Compounds affinities (Ki - nM) for the different adenosine receptor subtypes|
|XAC||Non selective antagonist||12||15||20||50|
|Theophylline||Non selective antagonist||4000||5000||18000||140000|
|Ciforadenant (CPI-444)||A2A antagonist||150||3.4||660||1600|
|Preladenant (SCH 420814)||A2A antagonist||> 20 000||5||> 20 000||>20 000|
|Istradefylline (KW-6002)||A2A antagonist||>10 000||40||>10 000||>10 000|
|AZD4635||A2A antagonist||900||15||660||> 10 000|
|MRS1706||A2B inverse agonist||150||325||30||> 300|
|MRS1220||A3 antagonist||325||37||> 500||1.6|
The graphs show the pattern of the dose-response curves obtained for five compounds displaying different selectivity profile.
In collaboration with Boehringer Ingelheim - Présentations scientifiaues
In collaboration with Bayer - Présentations scientifiaues
Challenge the limits of binding kinetics studies - Notes d'application
Binding Assays to measure therapeutic antitumor antibodies - Posters
The gold standard technology for receptor binding studies - Vidéos
Case study about kinetic binding characterization provided by the combination of Cisbio and Excellerate bioscience expertise. - Notes d'application
Get the brochure about technology comparison. - Brochures
Available On-demand - Vidéos
How to revolutionize your kinetic binding demonstration with HTRF kinase binding platform assays - Notes d'application
Choosing the right microplate reader ensures you’ll get an optimal readout. Discover our high performance reader, or verify if your lab equipment is going to be compatible with this detection technology.Let's find your reader